Phaseline

Targets › BRACHYURY

BRACHYURY: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: the race on BRACHYURY, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1
CEA, BRACHYURY, MUC1, KLK3, TBXTPhase 2Adenocarcinoma; Metastatic Colorectal CancerOct 2027

Conditions

Adenocarcinoma (1) Metastatic Colorectal Cancer (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

CEA (1) MUC1 (1) KLK3 (1) TBXT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.